17-May-2024
Incyte’s Share Buyback Program: A Buy Rating and Fundamental Value Increase
TipRanks (Thu, 16-May 4:07 AM ET)
Incyte’s Strategic Moves Amid Share Buyback and Pipeline Expansion: A Balanced Hold Rating
TipRanks (Thu, 16-May 12:26 AM ET)
Business Wire (Tue, 14-May 5:00 PM ET)
Incyte’s Strategic Financial Decisions and Market Positioning: A Hold Rating Analysis
TipRanks (Mon, 13-May 6:46 PM ET)
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Benzinga (Mon, 13-May 10:22 AM ET)
Incyte jumps 6%, intends to buy back $2B stock
Seeking Alpha News (Mon, 13-May 8:04 AM ET)
Incyte Corp Navigates Ownership with Strategic Stakeholder Deal
TipRanks (Mon, 13-May 7:33 AM ET)
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
Business Wire (Mon, 13-May 7:00 AM ET)
Incyte to Present at Upcoming Investor Conference
Business Wire (Thu, 2-May 8:00 AM ET)
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Business Wire (Tue, 30-Apr 7:00 AM ET)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Incyte trades on the NASDAQ stock market under the symbol INCY.
As of May 17, 2024, INCY stock price climbed to $57.10 with 1,455,128 million shares trading.
INCY has a beta of 0.80, meaning it tends to be less sensitive to market movements. INCY has a correlation of 0.16 to the broad based SPY ETF.
INCY has a market cap of $12.84 billion. This is considered a Large Cap stock.
Last quarter Incyte reported $881 million in Revenue and $.64 earnings per share. This fell short of revenue expectation by $-46 million and missed earnings estimates by -$.20.
In the last 3 years, INCY stock traded as high as $88.26 and as low as $50.27.
The top ETF exchange traded funds that INCY belongs to (by Net Assets): VTI, VOO, VO, SPY, USMV.
INCY has underperformed the market in the last year with a return of -11.5%, while the SPY ETF gained +29.1%. In the last 3 month period, INCY fell short of the market, returning -1.5%, while SPY returned +6.3%. However, in the most recent 2 weeks INCY has outperformed the stock market by returning +6.2%, while SPY returned +3.6%.
INCY support price is $55.93 and resistance is $57.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INCY stock will trade within this expected range on the day.